ARTICLE | Finance
Series A companies: The class of 2024
An analysis of the technologies behind last year’s biotech series A raisers predicts progress in nanoparticles, CAR cell therapies, degraders and ADCs
January 28, 2025 1:04 AM UTC
At least 152 biotech companies attracted series A investments in 2024, collectively raising over $6.7 billion. While that level of activity was similar to 2023, the number of megarounds nearly doubled.
An analysis from BioCentury’s BCIQ database identified 23 companies that raised $100 million or more last year, up from 10-13 companies in each of the prior four years...
Get Unlimited Access
To view this item, login or register for a free account.
Or Purchase This Article